Qiagen, known for its oncology offerings, is set to develop assays for the non-invasive prenatal testing market through a $40 million collaboration with Natera.
FDA gave the company the green light to end a trial of its LAP-BAND System early, saving the company more than $5 million.
Medtronic continued to strengthen its TAVR story with 5-year-data recently presented at ACC18. The company is battling it out with Edwards in the U.S. market, while Boston Scientific seeks to find footing after delaying commercialization of the Lotus Edge valve.
Laborie Medical Technologies is poised to get a leg up in the urology market by acquiring Cogentix Medical for about $239 million.
Strong results from the MOMENTUM 3 clinical trial could help Abbott take a significant part of the destination therapy portion of the LVAD market from Medtronic.
Cleveland Clinic Innovation Executive Director sees 3D Printing more suited for custom implants as opposed to mass producing products in healthcare.
GI Dynamics has been relatively quiet since it lost its CE mark for its Type 2 diabetes and obesity treatment device, but the company began making some noise when shareholders recently approved an offering of $2 million.
After several acquisitions and divestitures, LivaNova is showing strong momentum exiting the fourth quarter of 2017.
Dexcom beats Wall Street expectations in earnings despite mounting pressures from Abbott's Freestyle Libre and shifting diabetes market.
SQI Diagnostics and Predictive Health bring cardiovascular diagnostics to the forefront with the launch of a serum-based heart attack probability test.
Bivoentus is partnering with LifeLink Foundation to develop a next-generation bone allograft solution for use in spine and trauma surgery.